Petrelintide (ZP8396) Petrelintide (ZP8396) is a novel SC-administered, long-acting amylin analog, developed by Zealand Pharma (Sborg, Denmark), a peptide drug discovery and development company, which is currently in early-stage clinical trials (phase 1 clinical trials: ClinicalTrials.gov Identifier NCT05511025, NCT05096598 and NCT05613387) [116]
The protection versus repair paradigm Think of your skin as having two jobs
But, they work differently in your body
However, translating these findings into human applications is far from straightforward
The ingredient is professionally tested with stable activity, effectively awakening dormant hair follicles, repairing scalp micro-inflammatory damage, and accelerating scalp tissue repair